A retrospective, observational study assessing the relationship of clinical indicators and outcomes and explored the efficacy of capofungin addition to sulfamethoxazole-trimethoprim treatment in HIV-negative pneumocystis pneumonia patients.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 30 Jun 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Caspofungin (Primary) ; Cotrimoxazole (Primary)
Indications Pneumocystis pneumonia
Focus Therapeutic Use

Most Recent Events

30 Jun 2016 New trial record
18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight